ArticleFrontiers in public health2026
SARS-CoV-2 seroprevalence and extent of infection under-ascertainment in seven regions of Uzbekistan: a population-based serosurvey, May-July 2022.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate estimation of SARS-CoV-2 transmission was limited in many settings by incomplete diagnostic testing and case reporting. We conducted a population-based cross-sectional serosurvey in seven regions of Uzbekistan between May and July 2022 to estimate SARS-CoV-2 seroprevalence, describe self-reported vaccination coverage, and assess the implications for routine surveillance. A two-stage cluster sampling design was used to randomly select polyclinic catchment areas and registered residents aged ≥5 years. Survey weights accounted for selection probabilities, non-response, and regional population structure. Among 15,000 invited individuals, 13,173 completed both questionnaire and serological testing, corresponding to an 87.8% response rate. Weighted seroprevalence was 98.3% (95% CI 98.0-98.6), indicating extensive cumulative exposure through infection, vaccination, or both. Self-reported vaccination coverage was 59.0% among adults and substantially lower among children. Approximately 243,000 COVID-19 cases had been officially reported nationally by August 2022; however, this national count is not directly comparable with seroprevalence in the seven surveyed regions. Nevertheless, the high seroprevalence, including among groups with low vaccination coverage, is suggestive of substantial transmission not identified by routine case reporting. Population-based serosurveys can therefore complement routine surveillance when interpreted alongside vaccination and epidemiological data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.